兽医再生医学市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球兽医再生医学市场价值为 3.449 亿美元，预计到 2034 年将以 12.3% 的复合年增长率成长，达到 11 亿美元。推动这一增长的因素包括宠物数量的增加、人们对创新兽医治疗方案的认识不断提高，以及伴侣动物慢性和退化性疾病的稳定增加。随着宠物主人继续优先考虑为他们的动物提供高品质的医疗保健，对干细胞治疗和富血小板血浆疗法等再生疗法的需求正在增长。兽医越来越多地采用这些疗法来解决老年宠物和受伤动物的疼痛、发炎和组织修復问题。由于公私机构的大力资金支持，再生医学也变得越来越容易取得。随着生物技术的不断突破和临床证据的支持，再生方法的应用正在世界各地的兽医诊所中迅速扩展。微创和长期治疗方案的转变正在改变兽医实践中治疗慢性疼痛、肌肉骨骼损伤和退化性疾病的方式。

光是狗类市场在 2024 年就创造了 2.256 亿美元的收入，预计到 2034 年将达到 7.018 亿美元，这表明针对韧带损伤、关节炎和关节退化等常见问题的治疗方法的需求强劲。随着狗狗年龄的增长，它们更容易出现肌肉骨骼併发症，促使宠物主人和兽医寻求增强活动能力和减轻疼痛的先进解决方案。组织工程、干细胞疗法和富含血小板的血浆等治疗方法已被证明对恢復犬类患者功能和改善其生活品质特别有效。这一趋势正在推动诊所将再生医学融入老年或受伤狗的常规护理中。

按产品类别划分，干细胞疗法在 2024 年占据了 52.1% 的主导市场。由于已被证明具有促进组织再生、减少发炎和加速恢復的能力，该领域将继续蓬勃发展。在兽医临床试验不断增加和治疗用途日益广泛的推动下，自体和异体干细胞应用正在业界快速发展。这些进步使得干细胞疗法成为动物照护中最有前景和最广泛接受的治疗方式之一，特别是对于狗和马。

2024 年，美国兽医再生医学市场规模达 9,780 万美元，这得益于先进的医疗基础设施、高宠物收养率以及​​越来越多的患有关节和肌肉疾病的动物。行业领导者的出现、研发投入的增加以及专业再生服务的广泛普及进一步加强了该国的市场地位。支持性监管措施和以创新为重点的补助也在推动国内成长方面发挥关键作用。

为了占领更大的市场份额，Vetherapy、Animal Cell Therapies、Cell Therapy Sciences、VetStem、Lynch Biologics、Boehringer Ingelheim International、Dechra Pharmaceuticals、Regen Lab、Magellan Stem Cells、Enso Discoveries、Ardent、EquiCord 和 Medrego 等主要参与者正在投入创新和策略性研究。公司正在加强临床试验、投资下一代生物製剂并开发可扩展的再生疗法。与兽医诊所的合作、教育推广和全球分销策略对于满足日益增长的需求和加强市场地位仍然至关重要。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 慢性病和退化性疾病发生率上升
    • 再生医学的不断进步
    • 增加研发投入
    • 宠物拥有量和医疗保健支出不断增长
  • 产业陷阱与挑战
    • 治疗相关的不良反应
    • 监理合规挑战
• 成长潜力分析
• 监管格局
• 未来市场趋势
• 各国宠物数量
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按动物类型，2021 - 2034 年

• 主要趋势
• 狗
• 猫
• 马匹
• 其他动物类型

第六章：市场估计与预测：依产品类型，2021 - 2034 年

• 主要趋势
• 干细胞疗法
  • 自体
  • 同种异体
• 生物治疗
  • 富血小板血浆（PRP）
  • 生长因子
• 组织工程

第七章：市场估计与预测：按应用，2021 - 2034 年

• 主要趋势
• 骨科
• 创伤/伤口护理
• 其他应用

第八章：市场估计与预测：依最终用途，2021 - 2034 年

• 主要趋势
• 兽医院
• 兽医诊所
• 学术机构和研究机构

第九章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• Animal Cell Therapies
• Ardent
• Boehringer Ingelheim International
• Cell Therapy Sciences
• Dechra Pharmaceuticals
• Enso Discoveries
• EquiCord
• Lynch Biologics
• Magellan Stem Cells
• Medrego
• Regen Lab
• Vetherapy
• VetStem

The Global Veterinary Regenerative Medicine Market was valued at USD 344.9 million in 2024 and is estimated to grow at a CAGR of 12.3% to reach USD 1.1 billion by 2034. This growth is being fueled by a rising pet population, a growing awareness of innovative veterinary treatment options, and a steady increase in chronic and degenerative conditions among companion animals. As pet owners continue to prioritize high-quality healthcare for their animals, the demand for regenerative therapies like stem cell treatment and platelet-rich plasma therapy is gaining traction. Veterinarians are increasingly turning to these therapies to address pain, inflammation, and tissue repair in aging pets and animals with injuries. Regenerative medicine is also becoming more accessible thanks to strong financial support from both public and private institutions. With ongoing breakthroughs in biotechnology and supportive clinical evidence, the adoption of regenerative approaches is expanding rapidly across veterinary clinics worldwide. The shift toward minimally invasive and long-lasting treatment options is changing how chronic pain, musculoskeletal injuries, and degenerative disorders are being managed in veterinary practices.

The dog segment alone generated USD 225.6 million in 2024 and is expected to reach USD 701.8 million by 2034, signaling robust demand for therapies that target common issues like ligament injuries, arthritis, and joint degeneration. As dogs age, they're more susceptible to musculoskeletal complications, prompting both pet owners and veterinarians to seek advanced solutions that enhance mobility and reduce pain. Treatments such as tissue engineering, stem cell therapies, and platelet-rich plasma are proving especially effective in restoring function and improving quality of life for canine patients. The trend is pushing clinics to integrate regenerative medicine into routine care for aging or injured dogs.

By product category, stem cell therapy accounted for a dominant 52.1% market share in 2024. This segment continues to thrive due to its proven ability to promote tissue regeneration, minimize inflammation, and accelerate recovery. The industry is witnessing rapid development in both autologous and allogeneic stem cell applications, driven by increasing veterinary clinical trials and broader therapeutic use. These advances are making stem cell therapy one of the most promising and widely accepted treatment modalities in animal care, particularly for dogs and horses.

The U.S. Veterinary Regenerative Medicine Market brought in USD 97.8 million in 2024, backed by cutting-edge healthcare infrastructure, a high rate of pet adoption, and a growing number of animals suffering from joint and muscular disorders. The presence of leading industry players, rising R&D investments, and wider availability of specialized regenerative services have further strengthened the country's market position. Supportive regulatory initiatives and innovation-focused grants are also playing a key role in driving domestic growth.

To capture greater market share, key players such as Vetherapy, Animal Cell Therapies, Cell Therapy Sciences, VetStem, Lynch Biologics, Boehringer Ingelheim International, Dechra Pharmaceuticals, Regen Lab, Magellan Stem Cells, Enso Discoveries, Ardent, EquiCord, and Medrego are doubling down on product innovation and strategic research partnerships. Companies are ramping up clinical trials, investing in next-gen biologics, and developing scalable regenerative therapies. Partnerships with veterinary clinics, educational outreach, and global distribution strategies remain central to meeting growing demand and reinforcing market presence.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of chronic and degenerative conditions
    • 3.2.1.2 Growing advancement in regenerative medicine
    • 3.2.1.3 Increasing research and development investments
    • 3.2.1.4 Growing pet ownership and healthcare spending
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Treatment-related adverse effects
    • 3.2.2.2 Regulatory compliance challenges
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Pet population by country
• 3.7 Porter’s analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Animal Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Dogs
• 5.3 Cats
• 5.4 Horses
• 5.5 Other animal types

Chapter 6 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Stem cell therapy
  • 6.2.1 Autologous
  • 6.2.2 Allogeneic
• 6.3 Biological therapy
  • 6.3.1 Platelet-rich plasma (PRP)
  • 6.3.2 Growth factor
• 6.4 Tissue engineering

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Orthopedics
• 7.3 Trauma/ wound care
• 7.4 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospitals
• 8.3 Veterinary clinics
• 8.4 Academics and research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Animal Cell Therapies
• 10.2 Ardent
• 10.3 Boehringer Ingelheim International
• 10.4 Cell Therapy Sciences
• 10.5 Dechra Pharmaceuticals
• 10.6 Enso Discoveries
• 10.7 EquiCord
• 10.8 Lynch Biologics
• 10.9 Magellan Stem Cells
• 10.10 Medrego
• 10.11 Regen Lab
• 10.12 Vetherapy
• 10.13 VetStem